Biogen
NEWS
Biogen is buying Pfizer’s PF-04958242, a first-in-class, Phase IIb-ready drug to treat several neurological and psychiatric diseases, including schizophrenia.
Biogen and AbbVie have voluntarily pulled their Zinbryta for relapsing multiple sclerosis (MS) off the market after safety concerns.
Today, on this 11th World Rare Disease Day, life science companies, organization and activists have come together to raise awareness about these diseases and the needs of therapies for patients.
After a huge dry spell in M&A, 2018 is shaping up to be a great year for deal making.
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
Here is a look at the life science companies viewed as the most innovative in the world.
Despite the recent dismal news regarding Alzheimer’s drug development, the U.S. Food and Drug Administration (FDA) recently proposed new guidelines for developing drugs for the disease.
Shares dropped by 9.1 percent, the biggest intraday decline since June 2016.
This is a market like the world has never seen.
JOBS
IN THE PRESS